“Naturally better EBITDA margins will be there comparatively because instead of 20-29 percent it will be about 35-36 percent. This will give volume growth and also the profitability margins will grow up”, said Venkat Jasti, Chairman and CEO, Suven Life Sciences
| Subscribe To Our Free Newsletter |
